RedHill Biopharma (RDHL)

RedHill Biopharma - RedHills RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohns Disease

Register to leave comments

  • News bot April 30, 2026, 11:03 a.m.

    📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General